Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.

Saved in:
Bibliographic Details
Title: Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Authors: Alexis AF; Weill Cornell Medicine, Dermatology, 211 East 80th St, 2nd Floor, New York, NY, 10075, USA. alexisa@med.cornell.edu., Bukhalo M; Arlington Dermatology, Rolling Meadows, IL, USA., Cook-Bolden FE; Park South Medical, Bronx, NY, USA., Del Rosso JQ; JDR Dermatology Research Center, LLC, Las Vegas, NV, USA., Draelos ZD; Dermatology Consulting Services, High Point, NC, USA., DuBois JC; DermResearch, Inc., Austin, TX, USA., Ferris LK; Department of Dermatology, University of North Carolina, Chapel Hill, NC, USA., Forman SB; ForCare Medical Center, Tampa, FL, USA., Kempers SE; Minnesota Clinical Study Center, Fridley, MN, USA., Kircik LH; Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Indiana Medical Center, Indianapolis, IN, USA.; Physicians Skin Care, PLLC and Skin Sciences, PLLC, Louisville, KY, USA., Lain E; Sanova Dermatology, Austin, TX, USA., Moore AY; Arlington Research Center, Arlington, TX, USA.; Baylor University Medical Center, Dallas, TX, USA., Pariser DM; Eastern Virginia Medical School and Virginia Clinical Research, Inc., Norfolk, VA, USA., Raoof J; Encino Research Center, Encino, CA, USA., Zirwas MJ; Dermatologists of the Central States, Probity Medical Research, and Ohio University, Bexley, OH, USA., Seal MS; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Kato S; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Chu DH; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Krupa D; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Snyder S; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Burnett P; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA., Berk DR; Arcutis Biotherapeutics, Inc., Westlake Village, CA, USA.
Source: American journal of clinical dermatology [Am J Clin Dermatol] 2026 Jan; Vol. 27 (1), pp. 189-198. Date of Electronic Publication: 2025 Nov 01.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100895290 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1888 (Electronic) Linking ISSN: 11750561 NLM ISO Abbreviation: Am J Clin Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-1888
DOI:10.1007/s40257-025-00984-2